Results 191 to 200 of about 2,422,307 (349)

Governance and Update Process for Lifestyle Medicine Core Competencies and Definitions. [PDF]

Am J Lifestyle Med
Rea BL, Cheema S, Lanza S, Makinde MT, Matthews S, Palma M, Kadosh MA, Lapsa-Lešinske A, Karlsen MC.   +8 more
europepmc   +1 more source

Association between depression and perceived parental traits : results from a nationally representative South African survey

, 2011
Catherine Filippa Srubisky
openalex   +1 more source

Finding younger, representative representatives [PDF]

BMJ, 1992
openaire   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Generative AI voting: fair collective choice is resilient to LLM biases and inconsistencies. [PDF]

EPJ Data Sci
Majumdar S, Elkind E, Pournaras E.
europepmc   +1 more source

() Representative EPR spectra obtained from control (NCX-4040, A2780 cDDP cells) and NCX-4040 treatment (100 ?M for both A2780 WT and A2780 cDDP) groups

, 2011
Anna Bratasz, Karuppaiyah Selvendiran, Tomasz J. Wąsowicz, Andrey A. Bobko, Valery V. Khramtsov, Louis J. Ignarro, Periannan Kuppusamy   +6 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Patient and public involvement (PPI) reporting in maternal and neonatal clinical trials: an exploratory review. [PDF]

Trials
Hannon K, Daly D, Smith V.
europepmc   +1 more source

Meetings that represent [PDF]

Nature Methods, 2019
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source